14
Views
54
CrossRef citations to date
0
Altmetric
Research Article

Possible Mechanisms in Hepatocarcinogensis by the Peroxisome Proliferator Di(2-Ethylhexyl)Phthalate

, , &
Pages 65-102 | Published online: 22 Sep 2008

References

  • Reddy J. K., Lalwani N. D. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit. Rev. Toxicol. 1983; 12: 1–58
  • National Toxicology Program. (NTP Technical Report Series No. 217). Carcinogenesis bioassay of di(2-ethylhexyl)phthalate in F-344 rats and B6C3F1 mice. National Institutes of Health, Bethesda, MD 1982a
  • Tennant R. W., Margolin B. H., Shelby M. D., Zeiger E., Haseman J. K., Spaulding J., Caspary W., Resnick M., Stasiewicz S., Anderson B., Minor R. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 1987; 236: 933–941
  • Butterworth B. E. Nongenotoxic Mechanisms in Carcinogenesis (Banbury Report 25), T. J. Slaga. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1987; 397
  • Butterworth B. E. The genetic toxicology of di(2-ethylhexyl)phthalate(DEHP). Nongenotoxic Mechanisms in Carcinogenesis (Banbury Report 25), B. E. Butterworth, T. J. Slaga. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1987; 257–276
  • Griesemer R. A., Harper C., Calabrese E., Michalopoulos G., Rosenkranz H. S., Schneiderman M., Sipes I. G. Chronic hazard advisory panel on di(2-ethylhexyl)phthalate (DEHP). Report to the U.S. Consumer Product Safety Commission, Washington, DC September, 1985
  • Turnbull D., Rodricks J. V. Assessment of possible carcinogenic risk to humans resulting from exposure to di(2-ethylhexyl)phthalate (DEHP). J. Am. Coll. Toxicol. 1985; 4: 111–145
  • Drinking Water and Health. National Academy Press, Washington, DC 1986; 338–358
  • Warren J. R., Simmon V. F., Reddy J. K. Properties of hypolipidemic peroxisome proliferators in the lymphocyte [3H]thymidine and Salmonella mutagenesis assays. Cancer Res. 1980; 40: 36–42
  • Reddy J. K., Lalwani N. D., Reddy M. K., Qureshi S. Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenicity by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res. 1982; 42: 259–266
  • Glauert H. P., Reddy J. K., Kennan W. S., Sattler G. L., Rao V. S., Pitot H. C. Effect of hypolipidemic peroxisome proliferators on unscheduled DNA synthesis in cultured hepatocytes and on mutagenesis in Salmonella. Cancer Lett. 1984; 24: 147–156
  • Cattley R. C., Richardson K. K., Smith-Oliver T., Popp J. A., Butterworth B. E. Effect of peroxisome proliferator carcinogens on unscheduled DNA synthesis in rat hepatocytes determined by auto-radiography. Cancer Lett. 1986; 33: 269–277
  • Cattley R. C., Smith-Oliver T., Butterworth B. E., Popp J. A. Failure of the peroxisome proliferator WY-14,643 to induce unscheduled DNA synthesis in rat hepatocytes following in vivo treatment. Carcinogenesis 1988; 9: 1179–1183
  • Bridges B. A., Butterworth B. E. Indicators of Genotoxic Exposure (Banbury Report 13), I. B. Weinstein. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 1982; 580
  • Chemical Manufacturers Association (CMA). Health effects testing, phase I: Validation results. Phthalate esters program panel, voluntary test program, G. B. Cox, E. J. Moran. Chemical Manufacturers Association, Washington, DC 1982; Vol. 1
  • Putman D. L., Moore W. A., Schechtman L. M., Hodgson J. R. Cytogenetic evaluation of di(2-ethylhexyl)phthalate and its major metabolites in Fischer 344 rats. Environ. Mutgen 1983; 5: 227–231
  • Buttenvorth B. E., Bermudez E., Smith-Oliver T., Earle L., Cattley R., Martin J., Popp J. A., Strom S., Jirtle R., Michalopoulos G. Lack of genotoxic activity of di(2-ethylhexyl)phthalate (DEHP) in rat and human hepatocytes. Carcinogenesis 1984; 5: 1329–1335
  • Lutz W. K. Investigation of the potential for binding of di(2-ethylhexyl)phthalate (DEHP) to rat liver DNA in vivo, Environ. Health Perspect. 1986; 65: 267–269
  • Elliott B. M., Elcombe C. R. Lack of DNA damage or lipid peroxidation measured in vivo in the rat liver following treatment with peroxisomal proliferators. Carcinogenesis 1987; 8: 1213–1218
  • Goel S. K., Lalwani N. D., Fahl W. E., Reddy J. K. Lack of covalent binding of peroxisome proliferators nafenopin and Wy-14,643 to DNA in vivo and in vitro, Toxicol. Lett. 1985; 24: 37–43
  • Gupta R. C., Goel S. K., Earley K., Singh B., Reddy J. K. 32P-Post-labeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and in hepatocytes in vitro. Carcinogenesis 1985; 6: 933–936
  • Garvey L. K., Swenberg J. A., Hamm T. E., Popp J. A. Di(2-ethylhexyl)phthalate: Lack of initiating activity in the liver of female F-344 rats. Carcinogenesis 2987; 8: 285–290
  • Cayama E., Tsuda H., Sarma D. S.R., Farber E. Initiatio of chemical carcinogenesis requires cell proliferation. Nature 1978; 275: 60–62
  • Tsuda H., Lee G., Farber E. Induction of resistant hepatocytes as a new principle for a positive short-term in vivo test for carcinogens. Cancer Res. 1980; 40: 1157–1164
  • Glauert H. P., Beer D., Rao M. S., Schwarz M., Xu Y., Goldsworthy T. L., Coloma J., Pitot H. C. Induction of altered hepatic foci in rats by the administration of hypolipidemic peroxisome proliferators alone or following a single dose of diethyinitrosamine. Cancer Res. 1986; 46: 4601–4606
  • Rao M. S., Lalwani N. D., Reddy J. K. Sequential histologic study of rat liver during peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio-acetic acid (WY-14,643)-induced carcinogenesis. J. Natl. Cancer Inst. 1984; 73: 983–990
  • Préat V., Lans M., decerlache J., Taper H., Roberfroid M. Comparison of the biological effects of phenobarbital and nafenopin on rat hepatocarcinogenesis. Gann 1986; 77: 629–638
  • Rao M. S., Lalwani N. D., Scarpelli D. G., Reddy J. K. The absence of γ-glutamyl transpeptidase activity in putative preneoplastic lisions and in hepatocellular carcinomas induced in rats by the hypolipidemic peroxisome proliferator WY-14,643. Carcinogenesis 1982; 3: 1231–1233
  • Rao M. S., Usuda N., Subbarao V., Reddy J. K. Absence of γ-glutamyltranspeptidase activity in neoplastic lesions induced in the liver of male F-344 rats by di(2-ethylhexyl)phthalate, a peroxisome proliferator. Carcinogenesis 1987; 8: 1347–1350
  • Rao S. M., Subbaro V., Reddy J. K. Peroxisome proliferator-induced hepatocarcinogenesis: Histochemical analysis of ciprofibrate-induced preneoplastic and neoplastic lesions for γ-glutamyl trans-peptidase activity. J. Natl. Cancer Inst. 1986; 77: 951–956
  • Ward J. M., Diwan B. A., Ohshima M., Hu H., Schuller H. M., Rice J. M. Tumor-initiating and promoting activities of di(2-ethylhe-xyl)phthalate in vivo and in vitro, Environ. Health Perspec. 1986; 65: 279–291
  • Frazells J. H., Abernethy D. J., Boreiko C. J. Enhanced sensitivity of the C3H/10T1/2 cell transformation system to alkylating and chemotherapeutic agents by treatment with 12-O-tetradecanoylphor-bol-13-acetate Environ. Mutagen. 1984; 6: 81–89
  • Sanchez J. H., Abernethy D. J., Boreiko C. J. Lack of di(2-ethylhexyl)phthalate activity in the C3H/10T/1/2 cell transformation system.Toxicol. In Vitro 1987; 1: 49–53
  • Matthews E. J., DelBalzo T., Rundell J. O. Assays for morphological transformation and mutation to oubain resistance of Balb/3T3 cells in culture, Prog. Mutat. Res. 1985; 5: 639
  • Barrett C. J., Wong A., McLachlan J. A. Diethylstilbestrol induces neoplastic transformation of cells in culture without measureable somatic mutation at two lici. Science 1981; 212: 1402–1404
  • Hesterberg T. W., Barrett C. J. Dependence of asbestos- and mineral dust-induced transformation of mammalian cells in culture on fiber dimension. Cancer Res. 1984; 44: 2170–2180
  • Barrett C. J., Hesterberg T. W., Thomassen D. G. Use of cell transformation systems for carcinogenicity testing and mechanistic studies of carcinogenesis. Pharmacol. Rev 1984; 36: 53S–70S
  • Barrett C. J., Lamb P. W. Tests with the Syrian hamster embryo cell transformation assay. Prog. Mutat. Res. 1985; 5: 623–628
  • Sanner T., Rivedal E. Tests with the Syrian hamster embryo (SHE) cell transformation assay. Prog. Mutat.Res. 1985; 5: 665–671
  • Ashby J., de Serres F, Draper M., Ishidate J., Margolin B., Matter B., Shelby M. Evaluation of short-term tests for carcinogenesis. Prog. Mutat. Res. 1985; 5: 752
  • Parry E. M. Tests for effects on mitosis and the mototic spindle in Chinese hamster primary liver cells (CH1-L) in culture. Evaluation of short-term tests for carcinogenesis. Prog. Mutat. Rex 1985; 5: 474–485
  • Woodward K. N. Phthalate Esters: Toxicity and Metabolism. CRC Press, Boca Raton, FL 1988; Vol. 1 and 2
  • Cattley R. C., Conway J. G., Popp J. A. Association of persistent peroxisome proliferation and oxidative injury with hepatocarcinogenicity in female F344 rats fed di(2-ethylhexyl)phthalate for 2 years. Cancer Lett. 1987; 38: 15–22
  • Tomaszewski K. E., Aganval D. K., Melnick R. L. In vitro steady-state levels of hydrogen peroxide after exposure of male F-344 rats and female B6C3F1 mice to hapatic peroxisome proliferators. Carcinogenesis 1986; 7: 1871–1876
  • Mitchell F. E., Price S. G., Hinton R. H., Grasso P., Bridges J. W. Time and dose-response study of the effects on rats of the plasticizer di(2-ethylhexyl)phthalate. Toxicol. Appl. Pharmacol. 1985; 81: 371–392
  • Lake B. G., Kozlen S. L., Evans J. G., Gray T. J.B., Young P. J., Gangolli S. D. Effect of prolonged administration of clofibric acid and di(2-ethylhexyl)phthalate on hepatic enzyme activities and lipid peroxidation in the rat. Toxicology 1987; 44: 213–228
  • Reddy J. K., Reddy M. K., Usman M. I., Lalwani N. D., Rao M. S. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl)adipate with a hypolipidemic drug Environ. Health Perspect. 1986; 64: 317–327
  • Marsman D. S., Cattley R. C., Conway J. G., Popp J. A. Relationship of peroxisome proliferation and cell proliferation to the hepatocarcinogenicity of the peroxisome proliferators, di(2-ethylhe-xyl)phthalate and Wy-14,643. Cancer Rex 1988, in press.
  • Perera M. I., Katyal S. L., Shinozuka H. Suppression of choline-deficient diet-induced hepnatocyte membrane lipid peroxidation in rats by the peroxisome proliferators 4-chloro-6-(2,3-xylidino)-2-pyrimidi-nylthio (N- β-hydroxyethyl) acetamide and di(2-ethylhexyl)phthalate). Cancer Res. 1986; 46: 3304–3308
  • Hawkins J. M., Jones W. E., Bonner F. W., Gibson G. G. The effect of pereoxisome proliferators on microsomal, peroxisomal, and mitochondrial enzyme activities in the liver and kidney. Drug Metab. Rev. 1987; 18: 441–515
  • Rao M. S., Reddy J. K. Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 1987; 8: 631–636
  • Ochi T., Cerutti P. A. Clastogenic action of hydroperoxy-5,8,11,13-icosatetraenoic acids on the mouse embryo fibroblasts C3H/10T1/2. Proc. Natl. Acad. Sci. 1987; 84: 990–994
  • Hornsby P. J., Harris S. E. Oxidative damage to DNA and replicative lifespan in cultured adrenocortical cells. Exp. Cell. Res. 1987; 168: 203–217
  • Alexson S. A., Cannon B. A direct comparison between peroxisomal and mitochondrial preferences for fatty-acyl P-oxidation predicts channeling of medium-chain and very-long-chain unsaturated fatty acids to peroxidation. Biochem. Biophys. Acta 1984; 796: 1–10
  • Chance B., Sies H., Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 1979; 59: 527–605
  • Foerster E., Fahrenkemper T., Rabe U., Graf P., Sies H. Peroxisomal fatty acid oxidation as detected by H2O2 production in intact perfused rat liver. Biochem. J. 1981; 196: 705–712
  • Handler J. A., Thurman R. G. Catalase-dependent ethanol oxidation in perfused rat liver: Requirement for fatty acid-stimulated H2O2 production by peroxisomes. Eru. J. Biochem. 1988, in press.
  • Conway J. G., Neptun D. A., Garvey L. K., Popp J. A. Role of fatty acyl-CoA oxidase in the efflux of oxidized glutathione from perfused livers from rats treated with the peroxisome proliferating compound nafenopin. Cancer Res. 1987; 47: 4795–4800
  • Lalwani N. D., Reddy M. K., Qureshi S. A., Reddy J. K. Development of hepatocellular carcinomas and increased peroxisomal fatty acid β-oxidation in rats fed [4-chloro-6-(2,3-xylindino)-2-pyrimi-dinylthiolacetic acid (Wy, 14,643) in the semipurified diet. Carcinogenesis 1981; 2: 645–650
  • Goel S. K., Lalwani N. D., Reddy J. K. Peroxisome proliferation and lipid peroxidation in rat liver. Cancer Res. 1986; 46: 1324–1330
  • Brizzee K. R., Ordy J. M. Cellular features, regional accumulation, and prospects of modification of age pigments in mammals. Age Pigments, R. S. Sohal. Elsevier/North-Holland Biomedical Press. 1981; 102–145
  • Chio K. S., Reiss U., Fletcher B. L., Tappel A. L. Peroxidation of subcellular organelles: Formation of lipofuscin-like fluorescent pigments. Science 1969; 166: 1535–1536
  • Conway J. G., Tomaszewski K. E., Olson M. J., Cattley R. C., Marsman R. L., Popp J. A. Relationship of oxidative damage to the hepatocarcinogenicity with the peroxisome proliferators di(Zethylhe-xyl)phthalate and Wy-14,643. Carcinogenesis 1988, in press.
  • Price S. C., Hinton R. H., Mitchell F. E., Hall D. E., Grasso P., Blane G. F., Bridges J. W. Time and dose study on the response of rats to the hypolipidemic drug fenofibrate. Toxicology 1986; 41: 169–191
  • Conway J. G., Popp J. A. in vivo ethane exhalation and lipofuscin accumulation in livers of rats fed the peroxisome proliferator Wy-14,643. Proc. Amer. Assoc. Cancer Rex 1988; 29, abstract 608
  • Smith M. T., Thor H., Hartzell P., Orrenius S. The measurement of lipid peroxidation in isolated hepatocytes. Biochem. Pharmacol. 1982; 31: 19–26
  • Ekstrom T., Stahl A., Sigvardson K., Hogberg J. Lipid peroxidation in vivo monitored by ethane exhalation and malondialdehyde excretion in the urine after oral administration of chloroform. Acta Pharmacol. Toxicol. 1986; 58: 289–296
  • Hietanen E., Ahotupa M., Bereziat J., Bussacchini V., Carnus A., Bartsch H. Elevated lipid peroxidation in rats induced by dietary lipids and N-nitrosodimethylamine and its inhibition by indomethacin monitored via ethane exhalation 1987; 15: 93–96
  • Smith C. V. Evidence for participation of lipid peroxidation and iron in diquat-induced hepatic necrosis. in vivo, Mol. Pharmacol. 1987; 32: 417–422
  • Lindstrom T. D., Anders M. W. Effects of agents known to alter carbon tetrachloride hepatotoxicity and cytochrome P-450 levels on carbon tetrachloride-stimulated lipid peroxidation and ethane expiration in the intact rat. Biochem. Pharmacol. 1978; 27: 563–567
  • Hughes H., Smith C. V., Homing E. C., Mitchell J. R. High-performance liquid chromatography and gas chromatography-mass spectrometry determination of specific lipid pereoxidation products. in vivo, Anal. Biochem. 1983; 130: 431–436
  • Fears R., Baggaley K. H., Alexander R., Morgan B., Hindley R. M. The participation of ethyl 4-benzylloxybenzoate (BRL 10894) and other aryl-substituted acids in glycerolipid metabolism. J. Lipid Res. 1978; 19: 3–11
  • Takashima K., Ohyama K., Mori T., Takeyama S. Hypolipidemic effect of α-mono-p-myristyloxy- α'-methylcinnamoyl glycereol (LK-903) in rats. Biochem. Pharmacol. 1978; 27: 2631–2635
  • Yagasaki K., Okada K., Mochizuki T., Takagi K., Tsutomu I. Effect of 4-(4′-chlorobenzyloxy) benzyinicotinate (KCD-232) on triglyceride and fatty acid metabolism in rats. Biochem. Pharmacol. 1984; 33: 3151–3163
  • Parker R. A., Kariya T., Grisar J. M., Petrow V. 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipidemic fatty acid-like alkyloxyarylcarboxylic acids. J. Med. Chem. 1977; 20: 731–791
  • Fears R. Lipophilic xenobiotic conjugates: The pharmacological and toxicological consequences of the participation of drugs and other foreign compounds as substrates in lipid biosynthesis. Prog. Lipid Res. 1985; 24: 177–195
  • Albro P. W., Corbett J. T., Schroeder J., Reddy J. K. β-Oxidation of 2-ethyl-5-carboxypentyl phthalate in rodent liver. Biochim. Biophys. Acta 1987; 923: 196–205
  • Bronfman M., Amigo L., Morales M. N. Activation of hypolipidemic drugs to acyl-coenzyme A thioesters. Biochem. J. 1986; 239: 781–784
  • Lygre T., Aarsaether N., Stensland E., Aarsland A., Berge R. K. Separation and measurement of clofibroyl coenzyme A and clofibric acid in rat liver after clofibrate administration by reverse-phase high-performence liquid chromatography with photodiode array detection. J. Chromatog. 1086; 381: 95–105
  • Hertz R., Bar-Tana J. The acylation of proteins by xenobiotic amphipathic carboxylic acids in cultured rat hepatocytes. Biochem. J. 1988; 254: 39–44
  • Rao M. S., Lalwani N. D., Watanabe T. K., Reddy J. K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res. 1984; 44: 1072–1076
  • Tsuda H., Moore M. A., Asamoto M., Inoue T., Ito N., Satoh K., Ichihara A., Nakamura T., Amelizad Z., Oesch F. Effect of modifying agents on the phenotypic expression of cytochrome P-450, glutathione S-transferase molecular forms, microsomal epoxide hydrolase, glucosed-phosphate dehydrogenase and γ-glutamyltranspeptidase in rat liver preneoplastic lesions. Carcinogenesis 1988; 9: 547–554
  • Ito N., Fukushima S., Tsuda H. Carcinogenicity and modification of carcinogenic response by BHA, BHT and other antioxidants. CRC Crit. Rev. Toxicol. 1985; 15: 109–150
  • Elliott B. M., Dodd N. J.F., Elcombe C. R. Increased hydroxyl radical production in liver peroxisomal fractions from rats treated with peroxisome proliferators. Carcinogenesis 1986; 7: 795–799
  • Fahl W. E., Lalwani N. D., Watanabe T., Goel S. K., Reddy J. K. DNA damage related to increased hydrogen peroxide generation by hypolipidemic drug-induced peroxisomes. Proc. Natl. Acad. Sci. 1984; 81: 7827–7830
  • Kornbrust D. J., Barfknecht T. R., Ingram P. J. Effect of di(2-ethylhexyl)phthalate on DNA repair and lipid peroxidation in rat hepatocytes and on metabolic cooperation in Chinese hamster V-79 cells. Toxicol. Environ. Health 1984; 13: 99–116
  • Martelli A., Ferro M., Marinari V. M., Bassi A. M., Brambilla G. Unscheduled DNA synthesis in primary cultures of peroxidized rat hepatocytes. Med. Sci. Res. 1987; 15: 989–990
  • Olson M. J. DNA strand breaks induced by hydrogen peroxide in isolated rat hepatocytes. J. Toxicol. Environ. Health 1988; 23: 407–423
  • Bentley P., Bieri F., Mitchell F., Waechter F., Staubli W. Investigations on the mechanism of liver tumour induction by peroxisome proliferators. Arch. Toxicol. Suppl. 1987; 10: 157–161
  • Williams G. M., Williams H., Maruyama, Tanaka T. Lack of initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis. Carcinogenesis 1987; 8: 875–880
  • Cattley R. C., Marsman D. S., Popp J. A. Failure of the peroxisome proliferator Wy-14,643 to initiate growth-selectable foci in rat liver. Toxicology 1988, in press.
  • Rao M. S., Tatematsu M., Subbarao V., Ito N., Reddy J. K. Analysis of peroxisome proliferator-induced preneoplastic and neo-plastic lesions of rat liver for placental form of glutathione S-transferase and γ-glutamyltranspeptidase. Cancer Res. 1986; 46: 5287–5290
  • Rao M. S., Subbarao V., Reddy J. K. Increased resistance of peroxisome proliferator-induced hepatic lesions to iron overload in rats. Cancer Lett. 1986; 32: 33–39
  • Bannasch P. Preneoplastic lesions as endpoints in carcinogenicity testing. I. Hepatic preneoplasia. Carcinogenesis 1986; 7: 689–695
  • Farber E. Pre-cancereous steps in carcinogenesis. Their physiological adaptive nature. Biochim. Biophys. Acta 1984; 738: 171–180
  • Goldsworthy T. L., Hanigan H. M., Pitot H. C. Models of hepatocarcinogenesis in the rat—constraints and comparisons. CRC Crit. Rev. Toxicol. 1986; 17: 61–89
  • Kaufmann W. K., MacKenzie S. A., Kauffman D. G. Quantitative relationship between hepatocytic neoplasms and islands of cellular alterations during hepatocarcinogensis in the male F344 rat. Am. J. Pathol. 1985; 119: 171–174
  • Kaufmann W. K., MacKenzie S. A., Rahija R., Kaufman d. G. Quantitative relationship between initiation of hepatocarcinogenesis and induction of altered cell islands. J. Cell. Biochem. 1986; 30: 1–9
  • Kaufmann W. K., Rahija R. J., MacKenzie S. A., Kaufman D. G. Cell cycle-dependent initiation of hepatocarcinogenesis in rats by (±)-7r, 8t-dihydroxyl-9t, 10t-epoxy-7,8,9,10-tetrahydrobenzo(a)-pyrene. Cancer Rex 1987; 47: 3771–3775
  • Watanabe K., Williams G. M. Enhancement of rat hepatocellular-altered foci by the tumor promoter phenobarbital: Evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions. J. Natl. Cancer Inst. 1978; 61: 1311–1314
  • Scherer E. Neoplastic progression in experimental hepatocarcinogenesis. Biochim. Biophys. Acta. 1984; 738: 219–236
  • Préat V., de Gerelache J., Lans M., Taper H., Roberfroid M. Comparative analysis of the effect of phenobarbital, dichlorodiphenyltrichloroethane, butylated hydroxytoluene and nafenopin on rat hepatocarcinogenesis. Carcinogenesis 1986; 7: 1025–1028
  • Popp J. A., Garvey L. K., Cattley R. C. In vivo studies on the mechanism of di(2-ethylhexyl)phthalate carcinogenesis. Toxicol. Ind. Health 1987; 3: 151–163
  • Préat V., Roberfroid M. Modulation of rat hepatocarcinogenesis by peroxisome proliferators. Second International Conference on Anticarcinogenesis and Radiation Protection, Gaithersburg, MD, March, 1987, 8–12
  • Mochizuki Y., Furukawa K., Sawada H. Effects of various concentrations of ethyl-α-p-chlorophenoxyisobutyrate (clofibrate) on diethylnitrosamine-induced hepatic tumorigenesis in the rat. Carcinogenesis 1985; 3: 1027–1029
  • Cattley R. C., Popp J. A. Differences in the hepatic promotional activities of the peroxisome proliferator Wy-14,643 and phenobarbital in rats. Proc. Amer. Assoc. Cancer 1988; 29, abstract 659
  • Popp J. A., Garvey L. K., Hamm J. E., Swenberg J. A. Lack of hepatic promotional activity by the peroxisomal proliferating hepatocarcinogen di(2-ethylhexyl)phthalate. Carcinogenesis 1985; 6: 141–144
  • Oesterle D., Deml E. Promoting activity of di(2-ethylhe-xyl)phthalate in rat liver foci bioassay. J. Cancer Res. Clin. Oncol. 1988; 114: 133–136
  • Ward J. M., Rice J. M., Creasia D., Lynch P., Riggs C. Dissimilar patterns of promotion by di(2-ethylhexyl)phthalate and phenobarbital of hepatocellular neoplasia initiated by diethylnitrosamine in B6C3F1 mice. Carcinogenesis 1983; 4: 1021–1029
  • Ward J. M., Ohshima M., Lynch P., Riggs C. Di(2-ethylhexyl)phthalate but not phenobarbital promotes N-nitrosodiethylamine-initiated hepatocellular proliferative lesions after short-term exposure in male B6C3F1 mice. Cancer Lett. 1984; 24: 49–55
  • Schulte-Hermann R., Timmermann-Trosiener I., Schuppler J. Promotion of spontaneous preneoplastic cell in rat liver as a possible explanation of tumor production by nonmutagenic compounds. Cancer Res. 1983; 43: 839–844
  • Popp J. A., Scortichini B., Garvey L. K. Quantitative evaluation of hepatic foci of cellular alteration occurring spontaneously in Fischer-344 rats. Fund. Appl. Toxicol. 1985; 5: 314–319
  • National Toxicology Program. Carcinogenesis bioassay of di(2-ethylhexyl)adipate in F-344 rats and B6C3F1 mice (NTP Technical Report Series No. 212). National Institutes of Health, Bethesda, MD 1982
  • Ciriolo M. R., Mavelli I., Rotilio G., Borzatta V., Cristofari M., Stanzani L. Decrease of superoxide dismutase and glutathione peroxidase in livers of rats treated with hypolipidemic drugs. FEBS Lett. 1982; 144: 264–268
  • Elliott B. M., Elcombe C. R. Effects of reactive oxygen species produced by peroxisome proliferation in the livers of rats. Proc. Amer. Assoc. Cancer Res. 1985; 281(26, Abstract)
  • Reddy J. K., Rao M. S., Azamoff D. L., Sell S. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferation, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643), in rat and mouse liver. Cancer Res. 1979; 39: 152–161
  • Butterworth B. E., Loury D. J., Smith-Oliver T., Cattley R. C. The potential role of chemically-induced hyperplasia in the carcinogenic activity of the hypolipidemic carcinogens. Toxicol. Ind. Health 1987; 3: 129–148
  • Moody D. E., Rao M. S., Reddy J. K. Mitogenic effect in mouse liver induced by a hypolipidemic drug, nafenopin. Virchows Arch. Abt. B 1977; 23: 291–296
  • IARC Working Group. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some Pharmaceutical Drugs. International Agency for Research on Cancer, Lyon 1980; Vol. 24: 39–125
  • De La Iglesia F. A., Lewis J. E., Buchanan R. A., Marcus E. L., McMahon G. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 1982; 43: 19–37
  • Ganning A. E., Brunk U., Dallner G. Phthalate esters and their effect on the liver. Hepatology 1984; 4: 541–547
  • Hanefeld M., Kemmer C. L., Leonhardt W., Kunze K. D., Jaross W., Hailer H. Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis 1980; 36: 159–172
  • Blumcke S., Schwartzkopff W., Lobeck h., Edmondson N. A., Prentice D. E., Blane G. F. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis 1983; 46: 105–116
  • Gariot P., Barrat E., Mejean L., Pointel J. P., Drouin P., Debry G. Fenofibrate and human liver. Arch. Toxicol. 1983; 53: 151–163
  • Gariot P., Barrat E., Drouin P., Genton P., Pointel J. P., Foliquet B., Kolopp M., Debry G. Morphometric study of human hepatic modifications induced by fenofibrate. Metabolism 1987; 36: 203–210
  • Hanefeld M., Kemmer C., Kadner E. Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 1983; 46: 239–246
  • Svoboda D., Grady H., Azarnoff D. Microbodies in experimentally altered cells. J. Cell Biol. 1967; 35: 127–152
  • Gray R. H., De La Iglesia F. A. Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species. Hepatology 1984; 4: 520–530
  • Chemical Manufacturers Association (CMA). CMA reference PE 34.0-MM-BIB. The biochemical, histological and electron-microscopic examination of livers from monkeys. Chemical Manufacturers Association, Washington, DC 1987
  • Orton T. C., Adam H. K., Bentley M., Holloway B., Tucker M. J. Clobuzarit: Species differences in morphological and biochemical response of the liver following chronic administration. Toxicol. Appl. Pharmacol. 1984; 73: 138–151
  • Reddy J. K., Lalwani N. D., Qureshi S. A., Reddy M. K., Moehle C. M. Induction of hepatic peroxisome proliferation in nonrodent species, including primates. Am. J. Pathol. 1984; 114: 171–182
  • Lalwani N. D., Reddy M. K., Ghosh S., Barnard S. D., Molello J. A., Reddy J. K. Induction of fatty acid P-oxidation and peroxisome proliferation in the liver of rhesus monkeys by DL-040, a new hypolipidemic agent. Biochem. Pharmacol. 1985; 34: 3473–3482
  • Allen K. L., Green C. E., Tyson C. A. Comparative studies of peroxisomal enzyme induction in hepatocytes from rat, cynomolgus monkey and human by hypolipidemic drugs. Toxicologist 1987; 7(abstract 253)
  • Gray T. J.B., Lake B. G., Beamand J. A., Foster J. R., Gangolli S. D. Peroxisomal effects of phthalate esters in primary cultures of rat hepatocytes. Toxicology 1983; 28: 167
  • Mitchell A. M., Lhuquenot J. C., Bridges J. W., Elcombe C. R. Identification of the proximate peroxisome proliferator(s) derived from di(2-ethylhexyl)phthalate. Toxicol. Appl. Pharmacol. 1985; 80: 23–29
  • Elcombe C. R., Mitchell A. M. Peroxisome proliferation due to di(2-ethylhexyl)phthalate (DEHP): Species differences and possible mechanisms. Envir. Health Perspect. 1986; 70: 211–219
  • Butterworth B. E., Smith-Oliver T., Earle L., Lowry J. J., White R. D., Doolittle D. J., Working P. K., Cattley R. C., Jirtle R., Michalopoulos G, Strom S. S. Use of primary cultures of human hepatocytes in toxicology studies. Cancer Res. 1988, in press.
  • Svoboda D. J., Azarnoff D. L. Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res. 1979; 39: 3419–3428
  • Reddy J. K., Qureshi S. A. Tumorigenicity of the hypolipidemic peroxisome proliferator ethyl-α-p-chlorophenoxyisobutyrate (clofibrate) in rats. Br. J. Cancer 1979; 40: 476–482
  • Reddy J. K., Azamoff D. L., Hignite C. E. Hypolipidemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (Lond.) 1980; 283: 397–398
  • Reddy J. K., Rao M. S. Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J. Natl. Cancer Inst. 1977; 59: 1645–1650
  • Lalwani N. D., Reddy M. K., Qureshi S. A., Reddy J. K. Development of hepatocellular carcinomas and increased peroxisomal fatty acid β-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimi-dinylthiolacetic acid (Wy-14,643) in semipurified diet. Carcinogenesis 1981; 2: 645–650

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.